| __timestamp | Agios Pharmaceuticals, Inc. | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 165772000 |
| Thursday, January 1, 2015 | 35992000 | 196614000 |
| Friday, January 1, 2016 | 50714000 | 303251000 |
| Sunday, January 1, 2017 | 71124000 | 366406000 |
| Monday, January 1, 2018 | 114145000 | 434407000 |
| Tuesday, January 1, 2019 | 132034000 | 468711000 |
| Wednesday, January 1, 2020 | 149070000 | 516922000 |
| Friday, January 1, 2021 | 121445000 | 739560000 |
| Saturday, January 1, 2022 | 121673000 | 1002140000 |
| Sunday, January 1, 2023 | 119903000 | 1161300000 |
| Monday, January 1, 2024 | 156784000 | 1242157000 |
Unleashing the power of data
In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Incyte Corporation and Agios Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Incyte Corporation consistently outpaced Agios Pharmaceuticals in SG&A spending, reflecting its larger scale and broader market reach. In 2023, Incyte's SG&A expenses were approximately 10 times higher than Agios's, highlighting its significant investment in administrative and sales functions. Notably, both companies saw a steady increase in these costs, with Incyte's expenses growing by about 600% and Agios's by roughly 525% since 2014. This trend underscores the escalating costs associated with maintaining a competitive edge in the biotech industry. As these companies continue to innovate, their ability to manage these expenses will be pivotal in sustaining growth and profitability.
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Incyte Corporation
Sanofi and Incyte Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Incyte Corporation
Takeda Pharmaceutical Company Limited and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Incyte Corporation and CymaBay Therapeutics, Inc.
Incyte Corporation vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Incyte Corporation and MorphoSys AG: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Incyte Corporation and Geron Corporation
Selling, General, and Administrative Costs: Alpine Immune Sciences, Inc. vs Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Agios Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Arrowhead Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: Agios Pharmaceuticals, Inc. vs Travere Therapeutics, Inc. Trends and Insights